Status:
TERMINATED
MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus
Lead Sponsor:
University Hospital, Grenoble
Conditions:
Cytomegalovirus Infections
Inflammatory Bowel Diseases
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The main objective of this study is to demonstrate the relevance of Valganciclovir on recurrent bouts of cryptogenic inflammatory bowel diseases with infection by cytomegalovirus (CMV). The goal is to...
Detailed Description
The cytomegalovirus (CMV) is a DNA virus from the herpes virus family. It is passed on between humans and even if infection is widespread (50 to 80% of people older than 35 are CMV immunoglobulin G po...
Eligibility Criteria
Inclusion
- Patient suffering from Crohn's disease, ulcerative colitis, unclassifiable colitis or pouchitis.
- Disease needing to be treated by corticoids and/or immunosuppressive drugs.
- Infection by cytomegalovirus.
- New attack during the three previous months.
Exclusion
- Serious or complicated attack, needing to be operated.
- Patient suffering from a psychiatric disease or is uncooperative.
- Patient suffering from another serious disease.
- Patient already participating in another clinical trial.
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2007
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00237653
Start Date
February 1 2004
End Date
December 1 2007
Last Update
April 3 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gastroenterology Department - University Hospital of Grenoble
Grenoble, France, 38043